A Prospective Phase II Trial of Vinblastine and Methotrexate in Multivessel Intraluminal Pulmonary Vein Stenosis in Infants and Children
Authors:
- Jean A. ConnorJCJean A. Connor
- Kimberlee GauvreauKGKimberlee Gauvreau
- Muhammad MuneebMMMuhammad Muneeb
- Terry SaiaTSTerry Saia
- Mark W. KieranMKMark W. Kieran
- 11 November 2011
- journal article
- Published by Tech Science Press in Congenital Heart Disease
- Vol. 6 (6) , 608-623
Abstract
Objective. To determine the safety and efficacy of the chemotherapeutic agents vinblastine and methotrexate in the treatment of children with progressive multivessel intraluminal pulmonary vein stenosis (PVS). Methods. Children received weekly vinblastine and methotrexate for a period of 1 year. Outcomes (for patients receiving ≥1 month of chemotherapy) were classified separately for patients with isolated PVS and PVS with congenital heart disease (CHD). Primary efficacy outcome was “response to treatment” categorized by echocardiographic criteria of response. Survival to 1 year was also evaluated. All adverse events were classified according to Cancer Therapy Evaluation Program, Common Terminology Criteria version 3.0. Events were further classified as related to chemotherapy, cardiac, or other causes. Results. Among 29 patients enrolled, 28 received at least one dose of chemotherapy and were evaluable for toxicity, while 23 were evaluable for response (21 CHD, 2 isolated). Both patients in the isolated group had progressive disease and died. Overall, 33% (7/21) of patients with PVS and CHD had stable disease; 1-year survival of 38%; and four patients continue in remission (93, 96, 124, and 125 months after treatment initiation). While both cardiac-related (19%) and chemotherapy-related (53%) toxicities were common, most were asymptomatic laboratory changes. Grade 3 (13%) and grade 4 (4%) toxicities were reversible, and no treatment-related grade 5 toxicities were observed. Conclusion. We report on the first prospective trial of chemotherapy for infants and children targeting the presence of myofibroblastic cells within the lesions of PVS based on myofibroblastic proliferation associated with desmoid tumors of infancy. The toxicity profile resulted in numerous treatment delays and interruptions that, combined with limited information on the natural history of PVS in this patient population, hampered our ability to determine the true efficacy of this approach. These results will be important as a baseline for clinical trials in this patient population.Keywords
This publication has 29 references indexed in Scilit:
- First‐line therapy of generalized infantile myofibromatosis with low‐dose vinblastine and methotrexatePediatric Blood & Cancer, 2008
- Pulmonary Vein Stenosis: Prematurity and Associated ConditionsPediatrics, 2008
- Vinblastine and Methotrexate for Desmoid Fibromatosis in Children: Results of a Pediatric Oncology Group Phase II TrialJournal of Clinical Oncology, 2007
- Multimodal Treatment of Children With Unresectable or Recurrent Desmoid Tumors: An 11-Year Longitudinal Observational StudyJournal of Pediatric Hematology/Oncology, 2004
- Multicentric Infantile Myofibromatosis in the CraniumNeurosurgery, 1995
- Congenital Generalized Myofibromatosis: A Disseminated Angiocentric MyofibromatosisPediatric Pathology & Laboratory Medicine, 1995
- Fibroblastic-Myofibroblastic Tumors in Children and Adolescents: A Clinicopathologic Study of 108 Examples in 103 PatientsPediatric Pathology, 1991
- Infantile Myofibromatosis: A Review of Clinicopathology with Perspectives on New Treatment ChoicesPediatric Dermatology, 1988
- Congenital pulmonary vein stenosisThe American Journal of Cardiology, 1984
- Congenital stenosis of individual pulmonary veins: Clinical spectrum and unsuccessful treatment by transvenous balloon dilationThe American Journal of Cardiology, 1982